CORCEPT THERAPEUTICS INCCORTEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 15.90% | 16.4M | — | 2024-01-22 |
| The Vanguard Group | 9.25% | 9.5M | — | 2024-02-13 |
| Nos. of above persons | 8.00% | 8.3M | ▲ +1.48pp | 2024-03-27 |
| Joseph K. Belanoff | 6.10% | 6.6M | — | 2024-02-12 |
| G. Leonard Baker, Jr. | 5.30% | 5.5M | — | 2024-02-14 |
Insider Transactions
Net 90d: −$354.8K · buys $3.31M / sells $3.67MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-07 | William Guyer | Chief Development Officer | Option exercise | 20.0K | $21.65 | $433.0K |
| 2026-04-07 | William Guyer | Chief Development Officer | Sell (open market) | 20.0K | $40.97 | $819.4K |
| 2026-04-06 | WILSON JAMES N | Director | Gift | 5.0K | $0.00 | $0 |
| 2026-03-25 | BELANOFF JOSEPH K | Chief Executive Officer | Sell (open market) | 26.2K | $50.07 | $1.31M |
| 2026-03-20 | WILSON JAMES N | Director | Gift | 4.0K | $0.00 | $0 |
| 2026-03-20 | William Guyer | Chief Development Officer | Option exercise | 11.8K | $21.65 | $254.8K |
| 2026-03-20 | William Guyer | Chief Development Officer | Sell (open market) | 11.8K | $36.01 | $423.7K |
| 2026-03-17 | BAKER G LEONARD JR | Director | Buy (open market) | 75.8K | $33.00 | $2.50M |
| 2026-03-17 | BAKER G LEONARD JR | Director | Buy (open market) | 24.2K | $33.56 | $812.8K |
| 2026-03-13 | WILSON JAMES N | Director | Gift | 28.0K | $0.00 | $0 |
1–10 of 31
Page 1 / 4